Squarepoint’s AYTU BioPharma AYTU Stock Holding History

Squarepoint’s Portfolio AYTU Stock Details AYTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-504	Closed	-$14K	–	2815
2021 Q4	$14K	Buy	+504	New	+$21.8K	﹤0.01%	3093
2021 Q3	–	Sell	-1,724	Closed	-$173K	–	2901
2021 Q2	$173K	Buy	+1,724	New	+$202K	﹤0.01%	2883
2021 Q1	–	Sell	-1,743	Closed	-$208K	–	3106
2020 Q4	$208K	Buy	+1,743	New	+$317K	﹤0.01%	2478
2020 Q3	–	Sell	-213	Closed	-$60K	–	2484
2020 Q2	$60K	Buy	+213	New	+$64.5K	﹤0.01%	2080

Other funds holding AYTU

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Squarepoint's AYTU Position: Q1 2022 in Review

Squarepoint sold out of AYTU BioPharma (AYTU) in Q1 2022, closing a stake of 504 shares — an estimated $14K sold.

Squarepoint first reported a position in AYTU in Q2 2020 and held it in 4 quarters. The position peaked at $208K in Q4 2020. 32 funds tracked by Wall St. Rank hold AYTU as of Q1 2022.

Squarepoint reported no remaining AYTU BioPharma position as of Q1 2022 after selling out during the quarter.
Squarepoint sold 504 AYTU BioPharma shares in Q1 2022, an estimated $14K.
Squarepoint first reported a position in AYTU BioPharma in Q2 2020 and held it in 4 quarters.
Squarepoint's AYTU BioPharma position peaked at $208K in Q4 2020.
32 funds tracked by Wall St. Rank held AYTU BioPharma as of Q1 2022.

Based on Squarepoint's 13F filing for Q1 2022, filed 16 May 2022.